fashion -WSS

fashion

author：Wikipedia 2025-09-30 22:27:43 - browse：82315

Mayo Clinic, in Rochester, Minnesota on — Photo by KEREM YUCEL/AFP via Getty Images

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： AI for drug discovery: Experts on separating hype from reality

hotspot

knowledge

hotspot

WSS

HHS's proposed rule does nothing to address the climate crisis

Novel spinal cord stimulator treats paralysis without surgery

Roche drug slashes death risk in early

Roivant's CEO is a star, but biotech's black hole persists

Lawmakers grill UnitedHealth CEO on Change cyberattack

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

fashion

focus

Tori Bowie and the unacceptable rates of Black maternal death

Study on Amgen’s bispecific immunotherapy produces positive data

The high cost of giving birth even with insurance

AI for drug discovery: Experts on separating hype from reality

As demand for Covid shots wanes, Moderna seeks its next success

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

As demand for Covid shots wanes, Moderna seeks its next success

The problems with dementia villages

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

Study on Amgen’s bispecific immunotherapy produces positive data

ADCs take center stage as promising cancer treatments

STAT Summit: Ending the crisis of Black deaths in the U.S.

Questions loom on AstraZeneca cancer drug as safety concerns ebb

The creative science of coining drug names

Welsh Carson private equity firm escapes from FTC antitrust case

hotspot

knowledge

hotspot

entertainment